Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
diquafosol + rebamipide
- Development stage
- Unknown
- Lead developer
- Santen Pharmaceutical
- Modality
- Small Molecules
- Administration
- Ophthalmic
01
Overview
Diquafosol and rebamipide are two distinct ophthalmic agents used for the treatment of dry eye disease (DED). Diquafosol is a small molecule P2Y2 receptor agonist that stimulates the secretion of water and mucin from conjunctival epithelial cells and goblet cells. Rebamipide is a quinolinone derivative that increases mucin levels on the ocular surface and possesses anti-inflammatory properties. This specific entry refers to a Phase 4 clinical trial conducted by Korea University Anam Hospital (NCT05443308) that utilized a randomized, double-blind, paired-eye design to compare the immediate therapeutic and mucin-secreting effects of 3% diquafosol and 2% rebamipide in patients with DED.
- Brand names
- Rebam K
- Other names
- diquafosol tetrasodiumrebamipide
02
Targets
P2RY2 (P2Y Purinoceptor 2)PPARG (Peroxisome proliferator-activated receptor gamma)
Beyond the preview
Go deeper on diquafosol + rebamipide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on diquafosol + rebamipide.